Erratum to: A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses (Pharmaceutical Research DOI: 10.1007/s11095-012-0686-8);A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses

Pharmaceutical Research

Volumn 29, Issue 6, 2012, Pages 1650-1657

  Klier, John ^a   Fuchs, Sebastian ^a   May, Anna ^a   Schillinger, Ulrike ^b   Plank, Christian ^b   Winter, Gerhard ^a   Gehlen, Heidrun ^c   Coester, Conrad ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

CpG ODN; gelatin nanoparticles; hypersensitivity; immunotherapy; inhalation

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 2216; CYTOKINE; GELATIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 10; NANOPARTICLE; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG EFFICACY; HORSE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LUNG LAVAGE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT DISEASE; REMISSION; RESPIRATORY TRACT ALLERGY; TH1 CELL; TH2 CELL;

EID: 84862647193     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0760-2     Document Type: Erratum

References (30)

1. A Moreno-Aspitia EA Perez 2005 Nanoparticle albumin-bound paclitaxel (ABI-007). A newer taxane alternative in breast cancer Future Oncol 1 755 762 16556053 10.2217/14796694.1.6.755 1:CAS:528:DC%2BD28XnsFY%3D
2. K Xiao J Lou WL Fowler Y Li JS Lee L Xing, et al. 2009 A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer Biomaterials 30 6006 6016 19660809 10.1016/j.biomaterials.2009.07.015 1:CAS:528:DC%2BD1MXhtVGqtLnK
3. Q Zhou X Sun L Zeng J Liu Z Zhang 2009 A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma Nanomedicine 5 419 423 19523421 10.1016/j.nano.2009.01.009 1:CAS:528:DC%2BC3cXls1ekug%3D%3D
4. JN Kline 2007 Immunotherapy of asthma using CpG Oligodeoxynucleotides Immunol Res 39 279 286 17917072 10.1007/s12026-007-0083-2 1:CAS:528: DC%2BD2sXhtlertbfM
5. J Vollmer AM Krieg 2009 Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Adv Drug Deliv Rev 61 195 204 19211030 10.1016/j.addr.2008.12.008 1:CAS:528:DC%2BD1MXjtFKltb4%3D
6. NE Robinson 2001 Recurrent airway obstruction (Heaves) In: Lekeux P, editor. Equine respiratory diseases. Ithaca: International Veterinary Information Service; 2001. Available from: http://www.ivis.org/special-books/ Leukeux/robinson/IVIS.pdf
7. V Gerber D Baleri J Klukowska-Rötzler JE Swinburne G Dolf 2009 Mixed inheritance of equine recurrent airway obstruction J Vet Intern Med 23 626 630 19645845 10.1111/j.1939-1676.2009.0292.x 1:STN:280:DC%2BD1MrivVejuw%3D%3D
8. G Senti P Johansen S Haug C Bull C Gottschaller P Müller, et al. 2009 Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial Clin Exp Allergy 39 562 570 19226280 10.1111/j.1365-2222.2008.03191.x 1:CAS:528:DC%2BD1MXksVKjsL0%3D
9. AM Krieg 2002 CpG motifs in bacterial DNA and their immune effects Annu Rev Immunol 20 709 760 11861616 10.1146/annurev.immunol.20.100301.064842 1:CAS:528:DC%2BD38XjtlWgtbw%3D
10. B Bohle 2002 CpG motifs as possible adjuvants for the treatment of allergic diseases Int Arch Allergy Immunol 129 198 203 12444316 10.1159/000066771 1:CAS:528:DC%2BD38XovFSitb0%3D
11. K Zwiorek C Bourquin J Battiany G Winter S Endres G Hartmann, et al. 2008 Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides Pharm Res 25 551 562 17912489 10.1007/s11095-007-9410-5 1:CAS:528:DC%2BD1cXivFOitbc%3D
12. C Bourquin D Anz K Zwiorek A-L Lanz S Fuchs S Weigel, et al. 2008 Targeting CpG oligodeoxynucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity J Immunol 181 2990 2998 18713969 1:CAS:528:DC%2BD1cXhtVSiu73F
13. C Wurzenberger C Bourquin S Heidegger S Fuchs D Anz S Weigel N Sandholzner G Winter C Coester S Endres 2010 Delivery of immunostimulatory RNA oligonucleotides by gelatin-based nanoparticles triggers an efficient antitumoral response J Immunotherapy 33 9 935 944 10.1097/CJI.0b013e3181f5dfa7
14. Klier J, May A, Fuchs S, Schillinger U, Plank C, Winter G, et al. Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles. J Vet Immunol Immunopathol. 2011;144(1-2):79-87.
15. C Coester H von Briesen K Langer J Kreuter 2006 Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake J Microencapsulation 17 187 193
16. V Gerber R Straub E Marti J Hauptman C Herholz M King, et al. 2004 Endoscopic scoring of mucus quantity and quality. Observer and horse variance and relationship to inflammation, mucus viscoelasticity and volume Equine Vet J 36 576 582 15581321 10.2746/0425164044864525 1:STN:280:DC%2BD2cngslOlsw%3D%3D
17. DT Umetsu R DeKruyff 2006 The regulation of allergy and asthma Imm Rev 212 238 255 10.1111/j.0105-2896.2006.00413.x 1:CAS:528:DC%2BD28XpvFegtLs%3D
18. MR van Scott JP Justice JF Bradfield E Enright A Sigounas 2000 IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice Am J Physiol Lung Cell Mol Physiol 278 667 674
19. A Taylor J Verhagen K Blaser M Akdis CA Akdis 2006 Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells J Immunology 117 433 442 10.1111/j.1365-2567.2006.02321.x 1:CAS:528:DC%2BD28XjsVGks70%3D
20. M Jurk J Vollmer 2007 Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation BioDrugs 21 387 401 18020622 10.2165/00063030-200721060-00006 1:CAS:528:DC%2BD1cXhtVOrsLY%3D
21. P Stock O Akbari G Berry G Freeman R DeKruyff DT Umetsu 2004 Induction of TH1-like regulatory cells that express Foxp3 and protect against airway hyperreactivity Nat Immunol 5 1149 1156 15448689 10.1038/ni1122 1:CAS:528:DC%2BD2cXoslSksbg%3D
22. K Ryanna V Stratigou N Safinia C Hawrylowicz 2009 Regulatory T cells in bronchial asthma Allergy 64 335 347 19220222 10.1111/j.1398-9995.2009.01972.x 1:CAS:528:DC%2BD1MXktlKku7o%3D
23. + CD25hi regulatory T cells in pediatric asthma J Allergy Clin Immunol 119 1258 1266 17412402 10.1016/j.jaci.2007.02.023 1:CAS:528:DC%2BD2sXkslersrg%3D
24. + regulatory T cells J Imm 173 4433 4442 1:CAS:528:DC%2BD2cXnslWmtr0%3D
25. C von Garnier LP Nicod 2009 Immunology taught by lung dendritic cells Swiss Med Wkly 139 186 192
26. AG Jarnicki H Conroy C Brereton G Donnelly D Toomey K Walsh, et al. 2008 Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signalling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics J Immunol 180 256 262
27. JP Lavoie K Maghni M Desnoyers R Taha JG Martin QA Hamid 2001 Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile Am J Respir Crit Care Med 164 1410 1413 11704587 1:STN:280:DC%2BD3Mnlt1Sltw%3D%3D
28. P Lewkowicz N Lewkowicz A Sasiak H Tchórzewski 2006 Lipopolysaccharide-activatde CD4+ CD25+ Tregulatory cells inhibit neutrophil function and promote their apoptosis and death J Immunol 177 7155 7163 17082633 1:CAS:528:DC%2BD28XhtFGrtrjI
29. I Carmalho T Lopes-Carvalho T Ostler S Zelenay M Haury J Demengeot 2003 Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide J Exp Med 197 403 411 10.1084/jem.20021633
30. C Montagnoli F Fallarino R Gaziano S Bozza S Bellocchio T Zelante, et al. 2006 Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism J Immunol 176 1712 1723 16424201 1:CAS:528:DC%2BD28XlsFymtw%3D%3D